Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: China Prompts Sell-Off In Europe; Insurers Fall

Mon, 08th Oct 2018 12:00

LONDON (Alliance News) - Share prices in London had slipped firmly into the red by midday on Monday following a slump in Chinese equities overnight."Europe is following the Asian lead, with a drastic 3% decline in Chinese indices providing an overwhelmingly bearish tone for early European trade. The decision from the Chinese central bank to reduce the amount of capital banks require to hold is expected to free up USD109 billion for the economy, this also highlights the expectation of further economic suffering in the country, with the US-China trade war looking likely to rumble on," said IG market analyst Joshua Mahony.Halma and Vodafone were among the fallers in the FTSE 100 on Monday, while insurers were bringing up the rear of the FTSE 250 following an update from Lancashire Holdings.The FTSE 100 was down 0.6%, or 44.64 points, at 7,273.90 by midday. The FTSE 250 was 0.6% lower, or 126.82 points, at 19,791.21. The AIM All-Share was down 1.3% at 1,055.14.The Cboe UK 100 was 0.7% lower at 12,344.24 and the Cboe UK 250 also declined 0.7% to 17,953.56, while the Cboe UK Small Companies was down 0.1% at 12,007.53.Over in mainland Europe at midday, the CAC 40 in Paris and DAX 30 in Frankfurt were both 0.8% lower.The biggest faller in the FTSE 100 on Monday was Halma, down 3.5% after Shore Capital downgraded the hazard detection firm to Hold from Buy. Another of Monday's losers, Vodafone, was also lower after a broker downgrade. Jefferies cut its rating on the telecommunications stock to Hold from Buy, leaving Vodafone shares trading down 2.4%.Meanwhile, Segro gained 1.7% after Goldman Sachs raised the property investor and developer to Buy from Neutral.Insurers were among those falling in the FTSE 250 following a third quarter warning from Lancashire Holdings, the stock down 5.5%.The insurer said it expects to post a negative return on equity for the third quarter of 2018 due to losses from a number of recent natural disasters including hurricane Florence and typhoons Jebi, Mangkhut and Trami. Lancashire, which provides specialty insurance and reinsurance products, estimates losses from recent natural catastrophe events to be in a range of USD25 million to USD45 million. It also expects to record a USD30 million net loss from its marine portfolio. Other insurers were hit in a negative read-across following the update, with Hiscox down 1.8% and Beazley down 3.3%.IP Group was down 3.0% after reporting that its portfolio company, Diurnal, did not see Chronocort meet its primary objective in a phase three trial.Chronocort is intended to treat congenital adrenal hyperplasia, an orphan condition in which patients have a block in cortisol production. The goal of the phase three trial was to "demonstrate the superiority of Chronocort to conventional therapy", a goal which was not met as both Chronocort and conventional therapy proved equivalent.Shares in Diurnal were a steep 61% lower at midday.Shares in fashion retailer French Connection jumped 29% as it mulled a sale of the business."The board confirms it is currently reviewing all strategic options in order to deliver maximum value for its shareholders, which includes the potential sale of the company," the struggling retailer said in a statement responding to weekend press reports.French Connection, however, added that there can be no certainty over an offer, nor as to the terms of any offer.In September, French Connection recorded a widened loss in the first half of its 2019 financial year on the back of store closures and a "tough" retail trading environment in the UK."French Connection has long been seen as a value trap - the business contains hidden value but ongoing problems with trading have seen the share price remain weak. A sale of the business could help to lift it out of the 'trap' as long as the suitor is prepared to invest some time and money in sorting out the bad bits and nurturing the good bits," commented Russ Mould, investment director at AJ Bell.In data on Monday, a quarterly survey from the British Chambers of Commerce said the UK economy is stuck in a rut due to Brexit uncertainties.The balance of manufacturing firms reporting a fall in domestic sales rose to 24, while that of services firms fell to 23. Domestic orders for manufacturing declined, while services reported improved domestic orders.In services, the export sales balance fell marginally to 14 and export orders held steady at 12 in the third quarter.The lobby warned that the slowdown in exports in the manufacturing sector, and many services firms seemingly giving up trying to hire new staff, should be cause for concern."There has never been a more important time for the government to bolster business investment, competitiveness and productivity, in the face of significant Brexit headwinds," Adam Marshall, Director General of the BCC said.Elsewhere, Chinese Foreign Minister Wang Yi gave US Secretary of State Mike Pompeo a cool reception Monday in Beijing, as he warned of "conflict and confrontation" between the two world powers.Wang told Pompeo the US has escalated trade frictions between the two economies, and undermined China's interests on issues such as Taiwan and other domestic and foreign policies, the state-owned China Daily reported."We demand the US stop the unwarranted accusations and wrongdoings against China immediately," Wang said, warning against the US "taking a wrong approach of conflict and confrontation."Pompeo is on an East Asia tour focused on deciding the next steps in North Korea's denuclearization.In the US on Monday, stock markets remain open as the Columbus Day is observed. The Dow Jones is called 0.3% lower, with the S&P 500 set to shed 0.2% and the Nasdaq seen tumbling a steep 1.4% at the open.While the US corporate and economic calendar is quiet on Monday, things begin to kick off at the end of the week with the start of third quarter earnings season. Results are due from banks such as Citigroup, JPMorgan Chase and Wells Fargo on Friday.
More News
2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

Read more
21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

Diurnal Primary Focus Remains On Progressing Flagship Products

Read more
20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Read more
24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Read more
14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

Read more
28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

Read more
28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

Read more
10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

Read more
24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

Read more
24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

Read more
28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

Read more
21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

Read more
20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

Read more
25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

Read more
10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.